Key PointsQuestionIs savolitinib monotherapy more effective than sunitinib monotherapy on progression-free survival (PFS) in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC)? FindingsIn this phase 3, open-label, randomized clinical multicenter study including 60 patients with MET-driven PRCC, the primary end point was PFS. Although study enrollment was closed early, PFS was not statistically different for patients who received savolitinib or sunitinib, and the safety profile was superior with savolitinib. MeaningFurther investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.
JAMA Oncology – American Medical Association
Published: Aug 29, 2020